Prelude Therapeutics Inc

Ownership Transactions Reported by 17 Insiders

Symbol
PRLD on Nasdaq
Location
175 Innovation Boulevard, Wilmington, DE

Insiders trading volume in the past year

Prelude Therapeutics Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Baker Bros. Advisors Lp Director, 10%+ Owner $56.6M Jun 14, 2024
Orbimed Advisors Llc Director, 10%+ Owner $38.2M May 22, 2023
Krishna Vaddi CEO, Director $1.58M +$99.3K +6.72% Dec 18, 2024
Jane Huang President, CMO $438K Oct 4, 2024
Laurent Chardonnet Chief Financial Officer $159K Mar 1, 2024
Bryant D. Lim CLO, Interim CFO, Corp Sec. $24.8K +$22.6K +1042% Dec 19, 2024
Christopher Pierce EVP and Chief of Business Oper $14.1K Sep 2, 2021
Peggy Scherle Chief Scientific Officer Mar 1, 2024
Andrew Combs Chief Chemistry Officer Mar 1, 2024
Deborah Morosini EVP, Chief of Clinical Affairs Feb 15, 2022
Martin Babler Director Jun 14, 2024
Paul A. Friedman Director Jun 14, 2024
Mardi Dier Director Jun 14, 2024
David P. Bonita Director, 10%+ Owner Jun 14, 2024
David J. Mauro Chief Medical Officer Oct 5, 2021
Victor Sandor Director Jun 14, 2024
Brian Piper Chief Financial Officer Aug 25, 2021

Recent Insider Transactions by Companies or Individuals for Prelude Therapeutics Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.